The U.S. Food and Drug Administration has granted 510(k) clearance to a new picosecond laser platform designed to address a persistent gap in tattoo removal: the reliable elimination of difficult ink colors including green, teal, and light blue. The device, which operates across three distinct wavelengths, is expected to reach clinical markets by early 2026.
What Was Cleared — and Why It Matters
The clearance covers a pulsed laser system delivering energy at 532 nm, 755 nm, and 1064 nm in picosecond pulses, with pulse durations ranging from 450 to 750 picoseconds depending on the selected mode. That combination of wavelengths in a single device is clinically significant because different ink pigments absorb laser energy most efficiently at specific wavelengths.
Red and orange inks respond well to 532 nm. Black and dark blue inks respond to 1064 nm. The 755 nm wavelength — the alexandrite range — is particularly effective against green and teal pigments, the colors that have historically frustrated practitioners and patients alike. Until recently, achieving meaningful clearance of green ink typically required multiple device types or yielded inconsistent results even after many sessions.
The new system consolidates all three wavelengths in one platform, reducing the need for providers to maintain and switch between separate devices mid-treatment.
How the 510(k) Pathway Works
FDA 510(k) clearance applies to Class II medical devices that are substantially equivalent to a legally marketed predicate device. The manufacturer must demonstrate that the new device has the same intended use and the same or no greater risks as the predicate. For laser systems in tattoo removal, this typically involves submitting bench testing data on pulse parameters, peak power, and spot size accuracy, along with biocompatibility documentation and labeling.
Importantly, 510(k) clearance is not FDA approval — it does not require randomized controlled clinical trials proving superiority to existing treatments. Critics of the pathway argue this means some cleared devices have limited clinical evidence. Proponents note that for devices with well-understood physical mechanisms, the pathway appropriately balances innovation speed with safety oversight.
The manufacturer submitted its application in May 2025 and received clearance in November, an unusually fast turnaround that FDA reviewers attributed to the completeness of the submission and the clear predicate lineage from earlier cleared picosecond devices.
Clinical Implications for Providers
Dermatologists and aesthetic practitioners who spoke with Blink Tattoo Removal described the clearance as practically useful rather than revolutionary. The underlying picosecond technology has been commercially available since the early 2010s, but triple-wavelength integration in one platform simplifies treatment workflows and potentially reduces treatment room overhead costs.
For patients, the clearance means that within the next treatment cycle, clinics that invest in the device will be able to treat a broader color palette more effectively without requiring referrals to specialty centers with multiple laser systems.
Pricing for the device has not been formally announced, but industry analysts estimate a list price in the range of $180,000 to $220,000, consistent with comparable multi-wavelength picosecond platforms already on the market.
The Long-Standing Color Problem in Tattoo Removal
Tattoo removal has always been easier for black and dark ink than for bright or light colors. This comes down to physics. Darker pigments absorb a wider spectrum of light, making them relatively agnostic to wavelength choice. Lighter and more chromatic pigments — particularly greens, teals, and light blues — have narrow absorption peaks that require precisely matched wavelengths to heat and shatter the ink particles effectively.
When ink particles absorb laser energy, they shatter into fragments small enough for the body's lymphatic and immune system to clear over weeks and months. If the wavelength is poorly matched to the pigment, much of the laser energy passes through or is reflected, generating heat in surrounding tissue without effectively fragmenting the ink. This produces pain, potential thermal injury, and minimal clearing — the worst possible outcome.
The triple-wavelength design directly addresses this by giving practitioners the correct photonic tool for each ink type in the same device, in the same session.
Market Context
The U.S. tattoo removal market is projected to reach approximately $1.4 billion by 2027, driven by a combination of rising tattoo prevalence, growing consumer awareness of removal options, and improving technology. Multiple device manufacturers — including established players and well-funded startups — are actively competing in the picosecond laser segment, which has largely supplanted older nanosecond Q-switched systems in new capital purchases at premium clinics.
The FDA clearance puts this new platform in a crowded but high-value market, competing against existing triple-wavelength and multi-platform offerings from other manufacturers. Differentiation will likely come down to pulse width consistency, spot size options, ergonomics, and after-sale service quality — factors that practitioners weigh heavily when making six-figure capital decisions.